texas oncology more breakthroughs. more victories



Michelle T. Ashworth, M.D.

Michelle T. Ashworth, M.D.

Provider Type: Physician

  • Hematology
  • Medical Oncology
Board Certifications:
  • Medical Oncology
  • Hematology

General Summary

Dr. Ashworth has a particular interest in skin cancers, head and neck cancer, immunotherapy, targeted therapy, and clinical research.

Dr. Ashworth is originally from the Bay Area and is now delighted to call Texas home. Dr. Ashworth speaks fluent Spanish.


  • Board Certifications in Hematology & Medical Oncology
    American Board of Internal Medicine
  • Clinical Fellow in Hematology-Oncology, Special Interests: Cutaneous Oncology, Head & Neck Cancer, Immunotherapy, Phase II-III Clinical Trials
    University of California San Francisco, San Francisco, CA 
  • Board Certification in Internal Medicine
    American Board of Internal Medicine 
  • Residency in Internal Medicine
    Scripps Clinic/Scripps Green Hospital, La Jolla, CA
  • Doctor of Medicine, Ethics Track
    Baylor College of Medicine, Houston, TX
  • Bachelor of Science in Human Biology, Social Aspects of Health & Disease
    University of Texas at Austin, Austin, TX

Medical Practice

  • Hematologist & Medical Oncologist, Texas Oncology Round Rock Cancer Center, (2014-present)
  • Multidisciplinary Tumor Board, St. David’s Medical Center Round Rock, (2014-present)
  • Hospice Austin Ethics Committee, 2015-present; Board of Directors, (2018-present)
  • Texas Oncology Medical Oncology Quality Committee, (2017-present)
  • Texas Oncology Central Texas Region Executive Committee, (2016-present)
  • Texas Oncology Environmental Impact Initiative Development (2018-present)
  • US Oncology Research Advanced Therapeutics Program, (2015-present)
  • Clinical Assistant Professor, Department of Internal Medicine, Texas A&M Health Science Center College of Medicine, (2015-2018)
  • Clinical Reviewer, Envoy Medical Systems, re Texas Department of Insurance, (2016-present)
  • Speaker, Cemiplimab for Advanced Cutaneous SCC, Sanofi Genzyme/Regeneron (2018-present)
  • Speaker, Diagnosis and Management of aHUS and PNH, Alexion Pharmaceuticals, (2016-present)
  • Speaker, Carcinoma of Unknown Primary, Biotheranostics (2017)
  • IO-ICON Advisory Group, Bristol-Myers Squibb (2015-2018)
  • US Oncology Community Practice & Management Advisory Board, Merck Sharp & Dohme (2018)
  • Melanoma Advisory Board, Array BioPharma, (2018-present)
  • CLL Advisory Board, DAVA Oncology, (2017)

Research Interest

Surgery Locations

Other Information

Accolades & Memberships

  • Texas Medical Association, Member (2014-present)
  • Travis County Medical Society, Member (2014-present)
  • American Association for Cancer Research, Member (2013-present)
  • American Society of Hematology, Member (2011-present)
  • American Society of Clinical Oncology, Member (2011-present)
  • American College of Physicians, Student Member (2004-2008); Associate Member (2008-2011)
  • BCM Class of 2008, Class Representative (2005-2006); Class President (2006-2008)
  • BCM Student Oncology Interest Group, Founder & President (2005-2006); Vice President, (2006-2008)

Community Service

  • Healing NET Foundation Supporter (2017-present); Faculty (2018-present)
  • SafePlace Volunteer (2017-present)
  • Black Fret Member (2017-2018)
  • Girlstart Volunteer and Sponsor (2016-present)
  • Austin Pets Alive! Supporter (2016-present)
  • UT Austin Dell Medical School Dermatology Residency Grand Rounds Speaker, "Update on Systemic Therapy in Advanced/Metastatic Cutaneous Squamous Cell Carcinoma (Jan 2019)
  • City of Round Rock Guest Speaker, “Skin Cancer in Central Texas: Prevention and Self Examination” (Sept 2015)
  • Texas Dermatological Society Guest Speaker, “Immunotherapy in Advanced Cutaneous Melanoma” (Dec 2014)
  • Leukemia/Lymphoma Society CME Presentation, “Updates in the Treatment of Myeloma, Leukemia and Lymphoma” (Dec 2014)
  • EQ Rounds Program Leader: New curriculum development for peer support, debriefing, and techniques in physician self-care among fellows (2013-2014)
  • Radiation Oncology Grand Rounds, Speaker, Systemic Therapy in Head & Neck Cancer (Dec 2013)
  • Dermatology Grand Rounds, Speaker, Immunotherapy in Advanced Cutaneous Melanoma (Oct 2013)
  • UCSF Medical School Course, Mechanisms, Methods, Malignancies (M3), Small Group Instructor (Nov 2012) 
  • UCSF Hematology-Oncology Fellowship Recruitment Committee, Member (July 2012-2014)
  • UCSF Hematology-Oncology Fellowship Orientation Committee, Member (March 2012-2014) 
  • UCSF Apex Fellows and Residents Advisory Committee (FRAG), Fellowship Representative, (2012-2013) 
  • First Graduate, Guest Speaker (2012-2013)
  • Scripps Green Hospital Ethics Committee, Member (2009-2011)
  • Saturday Morning Science, Medical Student Facilitator (2005-2008) 

  • White Coat Ceremony, Coordinator & Speaker (2005)
  • Office of Minority Student Recruitment & Retention, Student Liaison (2004-2008) 


  • The Role of Cytotoxic Chemotherapy in Advanced Melanoma

    Melanoma, 2015

  • Phase 1 Dose-Escalation Trial of Chk1 Inhibitor MK-8776 as Monotherapy and in Combination with Gemcitabine in Patients with Advanced Solid Tumors

    Journal of Clinical Oncology, 2015

  • Melanoma Immunotherapy

    Cancer Biology & Therapy, 2014

  • Management of a Patient With Advanced BRAF-Mutant Melanoma

    Journal of the National Comprehensive Cancer Network, 2014

  • Characteristics of Pyrexia in BRAFV600E/K Metastatic Melanoma Patients Treated with Dabrafenib and Trametinib in a Phase I/II Clinical Trial

    Annals of Oncology, 2014

Show all Publications
  • Combinatorial Approach to Treatment of Melanoma

    Hematology-Oncology Clinics: Melanoma, 2014

  • Cell-Specific Gene Expression in Langerhans Cell Histiocytosis Lesions Reveals a Distinct Profile Compared with Epidermal Langerhans Cells.

    Journal of Immunology, 2010

  • Comparison of FDG-PET Scans to Conventional Radiography and Bone Scans in Management of Langerhans Cell Histiocytosis

    Pediatric Blood & Cancer, 2009